ont-Saint-Guibert, Belgium – Mayo Clinic and Cardio3 Biosciences recently entered into a non-exclusive preferred access agreement. This agreement builds on a long established and productive relationship of licensing and research in the area of cardiac regeneration. The mutual hope for this work is that together Mayo Clinic and Cardio3 BioSciences can accelerate Mayo Clinic discoveries toward clinical application.
Under the collaboration agreement, the parties have agreed to regular periodic meetings to review Mayo Clinic’s regenerative medicine portfolio to identify areas and projects of mutual interest. The results of these conversations could potentially lead to cooperative research projects, license agreements or introductions to third parties to further the technology. The agreement does not prevent Mayo Clinic from working with other potential commercial partners in the same manner.
Mayo Clinic and Cardio3 BioSciences look forward to this ongoing collaboration and both believe that together they can continue to move promising technologies towards patients.
